Alisertib News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alisertib. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alisertib Today - Breaking & Trending Today

AURKA Pathway Gains Ground as Targetable Option in Metastatic Breast Cancer

The AURKA inhibitor alisertib has emerged as an agent of particular note, demonstrating early signals of efficacy with a manageable safety profile for the treatment of patients with locally advanced or metastatic breast cancer whose disease is resistant to endocrine therapies. ....

Mayo Clinic In Rochester , United States , Karthikv Giridhar , Tufiac Haddad , Antonio Dassoro , Houj Aurora , Digital Health , Mayo Clinic Comprehensive Cancer Center , Mayo Clinic College Of Medicine , American Society Of Clinical Oncology Annual Meeting , Mayo Clinic , Mayo Clinic College , Antoniod Assoro , Demonstrates Efficacy , Advanced Breast , Several Tumor , Clinical Oncology Annual Meeting , Cell Death , Aurora Kinase , Curr Oncol , Aurka Inhibitor , Tbcrc041 Trial ,

Alisertib Induces Early Signals of Efficacy in Endocrine-Resistant Breast Cancer

Alisertib as monotherapy and in combination with fulvestrant stands at the forefront of the clinical investigation of selective AURKA pathway inhibition in patients with endocrine-resistant advanced breast cancer, according to Tufia C. Haddad, MD. ....

United States , Tufiac Haddad , Antonio Dassoro , Practice Innovation , Mayo Clinic Comprehensive Cancer Center , Antoniod Assoro , Puma Biotechnology , Aurka Pathway , Endocrine Resistant Advanced Breast Cancer , A Phase 2 Trial Nct02860000 , Her2 Negative Metastatic Breast Cancer ,

Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting

Puma Biotechnology, Inc. , a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II study of alisertib plus paclitaxel versus paclitaxel alone in metastatic. | June 4, 2023 ....

United States , Baylor University , Saraa Byron , Sara Byron , Joycea Oshaughnessy , Alanh Auerbach , Joyce Oshaughnessy , Drug Administration , Puma Biotechnology Inc , European Commission , Breast Cancer Research , Research Associate Professor , American Society Of Clinical Oncology , Translational Genomics Research Institute Tgen , Cancer Genomics Division , Us Oncology Network , Jama Network , Puma Biotechnology , Clinical Oncology , Annual Meeting , Joyceo Shaughnessy , Jama Network Open , Breast Cancer , Metastaticposter Session , Integrated Cancer Genomics Division , Translational Genomics Research Institute ,